Indaptus completes first Decoy20 cohort; starts second cohort

Indaptus Therapeutics, Inc.

Three patients completed 28-day safety review; one grade 3 bradycardia (reversible) and two grade 3 AST increases resolved.
Other adverse events (chills, fatigue, vomiting, fever) were grade 1-2 and resolved quickly.
Immune activation observed via transient expression of cytokines/chemokines associated with innate and adaptive pathways.
Second cohort initiated after Safety Review Committee review per protocol.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.